3 resultat
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to pending U.S. application Ser. No. 14/561,091 entitled "Transdermal Cannabinoid Formulations", filed Dec. 4, 2014, now U.S. Pat. No. 9,375,417, issued Jun. 28, 2016, the disclosure of which is hereby incorporated by reference
BACKGROUND
The clinical usefulness of the cannabinoids, including 11.sup.9-tetrahydrocannabinol (/1.sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits, including, but not
BACKGROUND
The clinical usefulness of the cannabinoids, including .DELTA..sup.9-tetrahydrocannabinol (.DELTA..sup.9-THC), to provide analgesia, help alleviate nausea and emesis, as well as stimulate appetite has been well-recognized. Cannabinoids offer a variety of pharmacological benefits,